Inclusion Criteria:

          -  Patients with AML who have undergone AML cell harvest and cryopreservation as per
             protocol 16-593 or companion protocol 18-232.

          -  Patients must have had a minimum of 5x107 cells cryopreserved.

          -  Patients must be day 25-45 following allogeneic transplantation from either:

               -  Group A: HLA 8/8 or 7/8 matched related donor or HLA 8/8 matched unrelated donor,
                  as determined by antigen or allele level typing at HLA A,B,C, and HLA DRB1.

        OR

          -  Group B: Haplo-identical donor

               -  Patients must be ≥ 18 years old

               -  ECOG performance status ≤2 (Appendix A)

               -  Participants must have normal organ and marrow function as defined below:

          -  Total bilirubin ≤ 2.0 mg/dL (unless patient has Gilbert's disease)

          -  AST(SGOT)/ALT(SGPT) ≤ 3 × institutional upper limit of normal

          -  Creatinine ≤ 2.0 mg/dl

          -  Absolute neutrophil count > 1000

          -  Platelet count > 50,000

               -  The effects of DC/AML fusion cells on the developing human fetus are unknown. For
                  this reason, women of child-bearing potential and men must agree to use adequate
                  contraception (hormonal or barrier method of birth control; abstinence) prior to
                  study entry and for the duration of study participation. Should a woman become
                  pregnant or suspect she is pregnant while participating in this study, she should
                  inform her treating physician immediately.

               -  No evidence of ongoing grade 2 or higher aGVHD

               -  Must be on prednisone <20mg or other steroid equivalent

               -  Donor chimerism of bone marrow >60%

               -  Resolution of all transplant related grade III-IV toxicity as per CTC criteria
                  4.0

               -  Complete remission defined by absence of circulating blasts and less than 5%
                  blasts in the bone marrow

               -  Ability to understand and the willingness to sign a written informed consent
                  document.

        Eligibility Prior to Initiating Vaccination (Groups A and B)

          -  Assessments to be done between Day 45-75 post-transplant.

          -  At least 2 doses of fusion vaccine were produced

          -  No ongoing grade II-IV acute GVHD

          -  Prednisone requirement of < 20mg a day or steroid equivalent

          -  Participants must have normal organ and marrow function as defined below:

               -  Total bilirubin ≤ 2.0 mg/dL (unless patient has Gilbert's disease)

               -  AST(SGOT)/ALT(SGPT) ≤ 3 × institutional upper limit of normal

               -  Creatinine ≤ 2.0 mg/dl

               -  Absolute neutrophil count > 1000

               -  Platelet count > 50,000

          -  No uncontrolled acute infection

          -  No CTCAE grade ≥ 3 non-hematologic toxicity

          -  No serious intercurrent illness such as active acute infection, or significant cardiac
             disease characterized by clinically significant arrhythmia, active ischemic coronary
             disease or symptomatic congestive heart failure.

          -  Participants must be in a complete remission

        Pre-Treatment Criteria Prior to Decitabine (Group A Cohort 2)

          -  Assessments to be done within 3 days prior to initiation of therapy.

          -  Participants must have normal organ and marrow function as defined below:

          -  Total bilirubin ≤ 2.0 mg/dL (unless patient has Gilbert's disease)

               -  AST(SGOT)/ALT(SGPT) ≤ 3 × institutional upper limit of normal

               -  Creatinine ≤ 2.0 mg/dl

               -  Absolute neutrophil count > 1000

               -  Platelet count > 50,000

        Exclusion Criteria:

          -  Because of compromised cellular immunity, patients with a known history of HIV are
             excluded

          -  Leukemia with active CNS involvement

          -  Patients must not be pregnant. All premenopausal patients will undergo pregnancy
             testing. Men will agree to not father a child while on protocol treatment. Men and
             women will practice effective birth control while receiving protocol treatment.

          -  Participants may not be receiving any other Non-FDA approved study agents at the start
             of vaccination

          -  Uncontrolled intercurrent illness including uncontrolled active infection, symptomatic
             congestive heart failure, unstable angina pectoris, clinically significant cardiac
             arrhythmia, or psychiatric illness that would limit compliance with study
             requirements.

          -  Autoimmune or inflammatory disorders requiring active treatment with systemic steroids
             or immunosuppressive therapy limited to the following:

               -  GI Disorders: (including inflammatory bowel disease [e.g., ulcerative colitis,
                  Crohn's disease]

               -  Systemic lupus erythematosus

               -  Wegener's syndrome [granulomatosis with polyangiitis]

               -  Myasthenia gravis

               -  Graves' disease

               -  Rheumatoid arthritis

               -  Hypophysitis

               -  Uveitis